TAT 2017
 
Tuesday, March 7, 2017
08:30 - 10:10Plenary Session 5: Immuno-oncology (2): Novel immune modulators [More Info]
Chair: Aurélien Marabelle, Institut Gustave Roussy, Villejuif, France
Chair: Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada
08:30 - 08:50O5.1 New Combinations in Immunotherapy: TLR9 Agonist + Anti-PD-1 Therapy [More Info]
Robert Janssen, Dynavax Technologies, Berkeley, CA, USA
08:50 - 09:10O5.2 Bugs as Drugs, on the way to becoming a reality [More Info]
Laura Rosa Brunet, Immodulon Therapeutics, Uxbridge, United Kingdom
09:10 - 09:30O5.3 Combining immune checkpoints with cytotoxic chemotherapies [More Info]
François Ghiringhelli, Centre Georges-François Leclerc, Dijon Cedex, France
09:30 - 09:50O5.4 Boosting Immunity and The Cancer Immune Setpoint [More Info]
Daniel Chen, Genentech, San Francisco, CA, USA
09:50 - 10:10General discussion


10:15 - 10:40Break


10:40 - 12:20Plenary Session 6: Targeting the cell cycle [More Info]
Chair: David Hyman, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Chair: Gary Schwartz, Columbia University, New York, NY, USA
10:40 - 11:00O6.1 The Targeting of CDK4/6 Signaling Pathway: Defining a Biomarker for Response [More Info]
Gary Schwartz, Columbia University, New York, NY, USA
11:00 - 11:20O6.2 Exploring transcription-mediated replication stress and RNA-DNA hybrids as targets of anticancer drugs [More Info]
Andrés Aguilera, University of Seville, Sevilla, Spain
11:20 - 11:40O6.3 Exploiting the potential of ATR inhibitors [More Info]
Timothy Yap, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 - 12:00O6.4 MTH1 inhibitors and oxidative stress [More Info]
Thomas Helleday, SciLifeLab, Stockholm, Sweden
12:00 - 12:20General discussion


12:20 - 13:30Lunch
12:30 - 13:30Meet-the-Professor Session: How to give a talk and how to write a paper: Tips to advance your career [More Info]
Lee Ellis, MD Anderson Cancer Center, Houston, TX, USA


13:30 - 15:30Plenary Session 7: Targeted drug delivery: Next-generation antibody-drug conjugates and nanomedicines [More Info]
Chair: Giuseppe Giaccone, Georgetown University, Washington, DC, USA
Chair: Anthony Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
13:30 - 13:50O7.1 Abbvie/CytomX program on ADCs [More Info]
Rachel Humphrey, CytomX Therapeutics, South San Francisco, CA, USA
13:50 - 14:10O7.2 DCs with diverse payloads of tumor-killing agents [More Info]
Donald A. Bergstrom, Mersana Therapeutics, Cambridge, MA, USA
14:10 - 14:30O7.3 Rovalpituzumab tesirine (Rova-T) [More Info]
Giuseppe Giaccone, Georgetown University, Washington, DC, USA
14:30 - 14:50O7.4 New generation antibody-directed nanotherapeutics [More Info]
Andrew Sawyer, Merrimack Pharmaceuticals, Boston, MA, USA
14:50 - 15:10O7.5 Paving a Novel Approach to Developing Anticancer Combinations through Tumor-Targeting Nanomedicines [More Info]
Lawrence D. Mayer, Jazz Pharmaceuticals, Vancouver, Canada
15:10 - 15:30General discussion


15:30 - 16:00Break


16:00 - 17:50Plenary Session 8: Clinical genomic profiling in early-phase clinical studies [More Info]
Chair: Martijn Lolkema, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Chair: Filip Janku, The University Texas MD Anderson Cancer Center, Houston, TX, USA
16:00 - 16:20O8.1 Educational introduction: Genomic profiling techniques. Their pros and cons. [More Info]
Maria Arcila, Memorial Sloan Kettering Cancer Center, New York, NY, USA
16:20 - 16:50Controversy: “We Need Genomics in Early-Phase Drug Development”
16:20 - 16:40Pro presentation [More Info]
Emile Voest, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
16:40 - 16:50Discussion Controversy
16:50 - 17:10O8.2 Predictive biomarker evaluations and immunophenotyping in immunotherapy: the INSPIRE clinical trial [More Info]
Derek Clouthier, Princess Margaret Cancer Centre / University Health Network, Toronto, Canada
17:10 - 17:30O8.3 Decision support for genomically-selected trials [More Info]
Filip Janku, The University Texas MD Anderson Cancer Center, Houston, TX, USA
17:30 - 17:50General discussion